Literature DB >> 11733656

Intraarterial infusion of papaverine and change of cerebral hemodynamics in symptomatic cerebral vasospasm.

H Minami1, K Kuwamura, N Tamaki.   

Abstract

In 43 cases with symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage treated by intraarterial infusion of papaverine (IAP), we studied cerebral hemodynamics by measuring cerebral circulation time (CCT) using digital subtraction angiogram. CCT on the middle cerebral artery site was defined as CCT-LAV and on the anterior cerebral artery side as CCT-MAV. In the CCT-LAV, two phases were further defined; the arterial phase (CCT-A) and the capillary phase (CCT-CAP). Mean CCT-LAV before and after IAP was 6.35+/-1.69 sec, 4.91+/-1.56 sec, and mean CCT-MAV was 6.15+/-1.68 sec, 4.80+/-1.58 sec, each showing a significant shortening. Mean CCT-A before and after IAP was 0.274+/-0.105 sec, 0.226+/-0.066 sec and mean CCT-CAP was 6.00+/-1.62 sec and 4.60+/-1.55 sec. The shortening rate of CCT-A and CCT-CAP were 11.2+/-25.7% and 22.7+/-14.6% respectively. Our study confirmed that IAP shortened CCT and improved cerebral hemodynamics. Compared with CCT-A, CCT-CAP was shortened significantly, suggesting that IAP is working not only in the proximal vessels but also in the distal vessels, that is, effective for resolution of vasospasm in the view of cerebral microcirculation. Clinical outcome was not improved statistically, however, it is the fact that there are not a few cases improved neurologically and IAP is still useful for vasospasm as a means to directly dilate intracranial peripheral arteries.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11733656

Source DB:  PubMed          Journal:  Kobe J Med Sci        ISSN: 0023-2513


  5 in total

Review 1.  Intra-arterial papaverine infusions for the treatment of cerebral vasospasm induced by aneurysmal subarachnoid hemorrhage.

Authors:  James K Liu; William T Couldwell
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

2.  Manipulation of olfactory tight junctions using papaverine to enhance intranasal delivery of gemcitabine to the brain.

Authors:  Mansi Krishan; Gary A Gudelsky; Pankaj B Desai; Mary Beth Genter
Journal:  Drug Deliv       Date:  2013-10-14       Impact factor: 6.419

3.  Disruption of the blood-brain barrier by intra-arterial administration of papaverine: a technical note.

Authors:  Johannes Platz; Krisztina Baráth; Emanuela Keller; Anton Valavanis
Journal:  Neuroradiology       Date:  2008-09-13       Impact factor: 2.804

4.  Synthesis, acoustic stability, and pharmacologic activities of papaverine-loaded echogenic liposomes for ultrasound controlled drug delivery.

Authors:  Patrick H Kee; Todd A Abruzzo; Denise A B Smith; Jonathan A Kopechek; Boyu Wang; Shaoling L Huang; Robert C MacDonald; Christy K Holland; David D McPherson
Journal:  J Liposome Res       Date:  2008       Impact factor: 3.648

5.  Cerebral circulation time on DSA during endovascular treatment in WFNS grade I aneurysmal SAH patients-a predictor of DCI?

Authors:  Mark Schembri; Dagmar Verbaan; Bart J Emmer; Bert A Coert; Charles B L M Majoie; W Peter Vandertop; René van den Berg
Journal:  Neuroradiology       Date:  2021-07-14       Impact factor: 2.804

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.